Business Wire

NY-PHILIP-MORRIS-INTL

17.1.2024 10:31:28 CET | Business Wire | Press release

Share
A New Power Rises: White Paper from Philip Morris International Examines Societal Impact of the Fifth Estate

A white paper and survey released today by Philip Morris International Inc. (PMI) (NYSE: PM) examine the increasing influence of the Fifth Estate on public discourse. Encompassing a vast and diverse range of independent commentators, social media users, content creators, and online communities, the Fifth Estate poses unprecedented challenges and opportunities for established institutions by empowering individuals and citizen-led movements to drive change.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117191802/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Fifth Estate Landscape (Graphic: Business Wire)

“The Fifth Estate has become a significant societal force that can be leveraged for good or ill,” commented Dr. Moira Gilchrist, Chief Communications Officer, Philip Morris International. “On the one hand, the digital technologies that underpin it enable everyday people to stand up for what matters to them and help drive broad societal action. On the other, this new power center can favor emotion and ideology over facts, perpetuating polarization and misinformation. The question facing businesses, regulators, and society at large concerns how we can help steer this emerging force in a positive direction and address the valid concerns being expressed.”

Most people already interact with and rely on content generated by the Fifth Estate. According to the international survey conducted for PMI by independent research firm Povaddo—the results of which are presented in the paper, “Rethink Disruption: The Rise of the Fifth Estate”—two-thirds (67 percent) of respondents get news and information from nonmainstream sources.

These sources, the survey shows, impact people’s daily lives. When asked whether they had taken any action based on information or recommendations from Fifth Estate sources, respondents said they “talked to friends or family about something I read” (90 percent), “made an online purchase” (84 percent), “browsed a company’s website” (84 percent), and/or “made an in-store / in-person purchase” (79 percent). Notably, 69 percent reported that they had changed their views about a particular issue based on the information to which they were exposed.

Despite its growing prevalence, the Fifth Estate elicits concerns. Survey respondents stated that individuals and nonmainstream media pose a significant risk in terms of spreading misinformation (59 percent), sharing opinions without evidence (53 percent), and lacking transparency on sourcing (50 percent). Many respondents also highlighted its divisive potential, noting significant risks in terms of enabling the spread of radical ideologies (47 percent), exacerbating societal divisions (44 percent), and fueling cancel culture (40 percent).

“For PMI, embracing the voices of individuals—most vitally, adult smokers—and encouraging a people-centric debate involving policymakers, public health authorities, and civil society is critical to achieving our ambition of a smoke-free future—a future in which cigarettes have been made obsolete,” said Dr. Gilchrist. “The Fifth Estate can accelerate this future by prioritizing accuracy and science-based facts to empower those adults who would otherwise continue to smoke to change to better alternatives.”

As shown in the international survey, most people want governments, regulators, and platform owners to support positive change online by improving law enforcement’s ability to investigate and hold to account those who misuse internet platforms, implementing initiatives to improve transparency, and combating the generation and spread of misinformation. Individuals, too, have a role to play by verifying authenticity before sharing content, insisting on sources that fact-check information, and seeking out a variety of opinions to inform their views.

Read PMI’s latest white paper here.

About the survey

Povaddo conducted the online survey on behalf of PMI between December 6 and 13, 2023. The survey was fielded among 6,048 general population adults aged 21 and older in six countries: Brazil, Italy, South Africa, South Korea, the United Kingdom, and the United States. Approximately 1,000 interviews were administered in each country. Data were collected in a balanced way to reflect national population statistics and were not weighted. Results are accurate to a margin of error of ±1 percent at the overall level.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match–a leader in oral nicotine delivery–creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General snus as modified risk tobacco products. As of September 30, 2023, PMI’s smoke-free products were available for sale in 82 markets, and PMI estimates that approximately 19.7 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 36.2 percent of PMI’s total third-quarter 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240117191802/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Cessna Caravans to Boost USDA’s Fight Against Crop-Damaging Insects12.5.2026 17:00:00 CEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced that the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) has ordered three Cessna Caravan aircraft to support its sterile insect release program protecting citrus crops along the Rio Grande River in southern Texas. The new aircraft are expected to be delivered in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512676348/en/ Mission-Ready: The Cessna Caravan joins USDA’s fight to protect Texas citrus from invasive pests APHIS will use the Caravans to carry and release sterile insects that help prevent the spread of destructive pests, including fruit flies. The environmentally friendly technique helps safeguard fruit-bearing trees, reduce crop damage and protect agricultural industries that rely on healthy harvests. “These aircraft will help APHIS reach remote areas and carry out their important mission o

Elliptic Secures $120 Million Investment From Nasdaq Ventures, Deutsche Bank, One Peak and the British Business Bank12.5.2026 16:05:00 CEST | Press release

The institutions building the future of finance are choosing Elliptic as the standard on-chain analytics for digital assets Elliptic, the global leader in digital asset decisioning, today announced the closing of a $120 million Series D fundraise led by One Peak, with participation from Nasdaq Ventures, Deutsche Bank and the British Business Bank. The round values Elliptic at $670 million. These investors are among the most consequential institutions in global finance, together responsible for trillions in daily market activity, and they have placed their confidence in Elliptic. It is a signal about where the financial system is heading and who is trusted to underpin it, with Elliptic screening more of the global on-chain economy than any other private sector provider. The fundraise will accelerate Elliptic's mission to deliver the enterprise-grade on-chain analytics for the world's largest and most demanding banks, fintechs, government agencies and crypto and payments companies in the

Rigaku Accelerates Next-generation Semiconductor Metrology Development Leveraging World-Class Research Infrastructure12.5.2026 16:00:00 CEST | Press release

Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced the expansion of its development of metrology technologies for next-generation semiconductors, leveraging global research environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512888328/en/ Signing ceremony with imec held on April 9 As part of this initiative, Rigaku is working with imec, a world-leading semiconductor research and innovation hub headquartered in Belgium, under a three-year development program. Through this effort, Rigaku will advance its core X-ray technologies, including 3D device metrology, high-sensitivity detection of ultrathin films and trace elements, and non-destructive inspection of microscopic defects. As semiconductor devices evolve toward advanced architectures such as Gate-All-Around (GAA) and

Aster Guardians Global Nursing Award Announces Top 10 Finalists for 202612.5.2026 15:54:00 CEST | Press release

On the occasion of International Nurses Day, Aster DM Healthcare has announced the Top 10 finalists for the fifth edition of the Aster Guardians Global Nursing Award 2026, selected from over 134,000 registrations across 214* countries and economies. One of the Top 10 finalists will be honoured with the grand title and a prize of USD 250,000. Aster has appointed Ernst & Young LLP as the 'Process Advisors' of the award. EY has defined a three-stage evaluation process to determine the finalists and the winner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512872373/en/ Aster Guardians Global Nursing Awards 2026 - Top 10 Finalists (Photo: AETOSWire) The top 10 finalists for 2026 includes: Dr. Agimol Pradeep (United Kingdom), Dr. Aidah Alkaissi (Sweden), Dinah Sevilla (The Kingdom of Saudi Arabia), Dr. Hammoda Abu-Odah (Hong Kong SAR, China), Hindumbi Kaurom Kakkada (India), Johana Patricia Galvan Barrios (Colombia), Josephin

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress12.5.2026 15:30:00 CEST | Press release

Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts SessionOral and poster presentations to feature new data for INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with myeloproliferative neoplasms (MPNs) Incyte (Nasdaq:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden. “The breadth of the data that will be showcased at the 2026 EHA Congress highlights the continued advancement of our Hematology and Oncology pipeline and our focus on delivering differentiated medicines for patients with cancer and hematologic diseases,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “These presentations include findings fro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye